The Week In... Pharma (18-22/05)
  • Posted on: 22/05/2020
  • Category: Industry

The Week In... Pharma (18-22/05)

COVID-19: UK government streams £84m into vaccines research, a large-scale immunity study begins, RPS says pharmacists need greater power to ensure medication access, and the UK bulk buys hydroxychloroquine as a potential treatment.

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Operations Director, Mark Ward, on 07872 105 540 or email

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to, or give our offices a ring!

Gov't streams £84m into UK COVID-19 vaccines research

The funding includes £65.5 million for the vaccine being developed at the University of Oxford and £18.5 million for Imperial College London, as coronavirus vaccine trials accelerate.

Government begins large scale coronavirus immunity study

Up to 20,000 people are being asked to take part in a new government-funded coronavirus immunity study to further track the extent of the coronavirus spread across England, Scotland and Wales.

Pharmacists should have greater powers to ensure meds access, says RPS

The Royal Pharmaceutical Society (RPS) is calling for a change in medicines legislation that would allow community pharmacists to alter prescriptions to help minimise unnecessary treatment delays.

UK bulk buys hydroxychloroquine as potential Covid-19 treatment

Hydroxychloroquine, the anti-malarial drug being taken by Donald Trump as an unproven protection against coronavirus, is being bought in bulk by the UK in case it does turn out to be an effective Covid-19 treatment.

Moderna announces positive interim data from coronavirus vaccine trial

Moderna, Inc has announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).


While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.